Trial Profile
A Pilot Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Ifetroban (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 17 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2024 Planned number of patients changed from 60 to 35.
- 11 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2024.